EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Ioana Agache, Cezmi Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano Del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez-Arnau, Jan Gutermuth, Emma Guttman-Yassky, Marcus Maurer, Graham Ogg, Peck Y Ong, Liam O'Mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek Jutel

Onderzoeksoutput: Article

2 Citaten (Scopus)

Samenvatting

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

Originele taal-2English
Pagina's (van-tot)17-38
Aantal pagina's22
TijdschriftAllergy
Volume77
Nummer van het tijdschrift1
Vroegere onlinedatum29 jul 2021
DOI's
StatusPublished - jan 2022

Bibliografische nota

© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Vingerafdruk

Duik in de onderzoeksthema's van 'EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old'. Samen vormen ze een unieke vingerafdruk.

Citeer dit